Skip to content

Evaluation of the Usefulness of Imaging Methods and 3D Reconstruction in Percutaneous Closure Procedures of PVL.

Evaluation of the Usefulness of Imaging Methods and 3D Reconstruction in Percutaneous Closure Procedures of Paravalvular Leak (Clinical Trial).

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03371472
Acronym
VALE
Enrollment
18
Registered
2017-12-13
Start date
2017-05-08
Completion date
2018-07-14
Last updated
2019-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PVL - Paravalvular Leak

Brief summary

Paravalvular leak (PVL) is a condition that could be treated surgically or by the transcatheter deployment of the occluder devices (plugs). No PVL-specific occluder device is available on the market. VALE consortium plans to design and validate a new PVL dedicated devices (sizing balloon and occluder) in the context of computer 3D modeling, bench testing, preclinical evaluation and clinical research.

Detailed description

Transcatheter closure of PVL has emerged as a new treatment strategy that can be offered to patients with isolated PVL or to those with a very high risk of repeat surgery. The transcatheter approach involves deployment of occlude devices or coils and adopting either a percutaneous or a transapical approach. Limitation of such approach is the fact that no PVL-dedicated device is available on the market, and either vascular-specific plugs or other types of occluders used commonly for closure of ventricular septal defects or patent ductus arteriosus can be used. Several technical issues can make the procedure challenging. The primary problem is the localization and track of the canal which can be very difficult to engage and cross with the guidewire. Also the maneuverability of the guide catheter in often enlarged left atrium and the passage of the occluder device through narrow and serpiginous canal between calcified annulus and sewing ring is challenging. Clearly the limitations of current devices and increasing number of patients with significant PVL warrant the attempts to design and validate new PVL-dedicated devices in the context of computer modeling, bench testing, preclinical evaluation and clinical translation. These devices, as sizing balloon, could significantly simplify and shorten the procedure, decrease the risk of complications and incomplete defect closure as well as optimize cost-effectiveness of the procedure by decreasing number of the occluders.

Interventions

DEVICEVisualisation and measuring of paravalvular leak.

Visualisation and measurements of PVL by investigational sizing ballons made by Balton. The balloon is a modification of diameter and length of existing sizing ballons (AcuMark™, AMPLATZER™, Occlutech®).

Sponsors

KCRI
CollaboratorOTHER
Balton Sp.zo.o.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Intervention model description

In a group of patients with PVL there are defined two arms: one where PVL is located in mitral position (10 patients) and the second one where PVL is located in aortic position (10 patients).

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The presence of clinically and haemodynamically significant leakage around the surgically implanted cardiac prosthesis in the mitral or aortic position. * Heart surgery (heart team) disability after another cardiac surgery. * Technical feasibility of paravalvular leakage closure according to experienced operator.

Exclusion criteria

* Active endocarditis on artificial valve * Instability of artificial valve * The amount of cavity that prevents effective closure with an occluder * A history of acute coronary syndrome in less than 3 months before enrollment * Confirmed echocardiography of transplatin or transesophageal echocardiography * Hypersensitivity to contrast media * Any condition associated with the expected life expectancy of less than 6 months * Haemorrhagic diathesis * Significant renal impairment (eGFR \<30 mL/min/1.73m2)/chronic kidney disease at \>G3 stage * Pregnancy or lactation * Under 18 years of age * Patient unable or unwilling to give an informed consent to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Number of subjects with sizing procedure success (efficacy outcome)During index procedureSizing procedure is defined as effective when all following steps: device introduction into the leakage channel, filling in the leakage channel, obtaining a balloon image in the X-ray recording and removal of the balloon without complications are performed.
Incidence of a combined investigational device safety endpoint (safety outcome)During index procedureSafety of the investigational device defined as the occurrence/frequency of locking, fragmentation of the dimensioning balloon, enlargement of the leakage channel, locking of the mechanical prosthesis disks. Failure to use the investigational device defined as: locking of the dimensional balloon in site, fragmentation of the dimensional balloon, enlargement of the leakage channel dimension directly related to the application of the dimensional balloon, locking of the mechanical prosthesis disks. The failure will be assessed per investigational device and accounted for if at least one of four described events occur. Moreover, the frequency of each event will be additionally assessed and presented in per investigational device analysis.

Secondary

MeasureTime frameDescription
Size of paravalvular leakage after procedureDuring index procedureEvaluated in transesophageal echocardiography
Comparison of the size of the paravalvular leakage channel illustrated by a dimensional balloon obtained using 3D-TEE and computerized tomography echocardiographyDuring index procedureComparison of the measurements by sizing balloon to TEE and CT.
Frequency of major undesirable cardiovascular events30 days observationMACCE defined as: cardiac and non-cardiac death, stroke, TIA, myocardial infarction
Total radiation time.During index procedureThe total radiation time of the index procedure.
Duration of the dimensional procedure.During index procedureThe duration of the dimensional procedure during index procedure.
Total radiation dose.During index procedureThe amount of total radiation dose during index procedure.
Frequency and severity of hemorrhagic complications30 days observationThe hemorrhagic complications rated using BARC scale during 30 days follow up

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026